How compounded semaglutide came to be so widely prescribed
Semaglutide is the active ingredient in Novo Nordisk’s branded Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). Both are FDA-approved drugs manufactured under controlled pharmaceutical conditions. Compounded semaglutide is not the same product — it is not FDA-approved, it is not manufactured by Novo Nordisk, and PepScribe does not claim otherwise.
Compounded semaglutide spread through telehealth during the years when Novo Nordisk’s branded injections were listed in shortage and demand ran far ahead of supply. Nearly all of the public argument from that period was conducted in those terms, which is why so much of what you can still find online is framed around the shortage list.
The rule that governs the preparation itself is 21 U.S.C. § 353a, Section 503A of the Federal Food, Drug, and Cosmetic Act. It covers what a licensed pharmacy may prepare for an individual identified patient once a licensed prescriber has written for that patient. That is the transaction behind every compounded vial: one prescriber, one patient, one order.
What changed, and why the headlines keep moving
The FDA’s position on compounded GLP-1s moved several times after the initial shortage declaration. There were stretches when the agency called particular dosage strengths available while others were still listed, and courts issued injunctions at various points that paused enforcement action against compounders. The timeline is genuinely tangled, and that is before the coverage of it gets involved.
For a reader, the practical consequence is that an article from six months ago may describe a world that has already moved on. Headline-reading is a poor way to work out what applies to you.
The questions worth putting to a clinician are about your own prescription: whether semaglutide is appropriate for you, what the preparation contains, and what your dose schedule looks like. PepScribe’s semaglutide is a combination with cyanocobalamin, titrated per patient, and compounded preparations are not FDA-approved.
Every compounded vial traces back to one prescriber, one patient and one order, which is the part of the story the headlines leave out.
Where does it come from? 503A versus unregulated supply chains.
One of the most important — and least discussed — aspects of compounded semaglutide is where it actually comes from. Not all “compounded semaglutide” is the same:
- Licensed 503A pharmacies in the USA operate under state pharmacy board oversight and applicable FDA rules. They source bulk drug substances from registered manufacturers and are subject to inspection. PepScribe works exclusively with licensed 503A compounding pharmacies in the USA. No hidden overseas supply chain.
- Unregulated sources — overseas vendors, research chemical suppliers, and gray-market websites — are not subject to these controls. Purity, sterility, and accurate dosing from these sources cannot be verified. PepScribe does not source from or work with any unregulated supply chain.
- 503B outsourcing facilities face a different regulatory framework with more intensive FDA oversight and a separate set of rules. PepScribe’s pharmacy standard is 503A-only.
The sourcing distinction matters particularly during regulatory transitions. When legal compounding pathways tighten, some vendors shift to unregulated supply chains to maintain availability. Patients should ask explicit questions about where their compounded medication is prepared and under what oversight.
What is compounded semaglutide not?
A few claims circulate in popular media that are worth correcting directly:
- Compounded semaglutide is not “the same as Ozempic.” It contains the same active ingredient but is a different product prepared under different conditions without FDA approval of the compounded formulation.
- Compounded semaglutide is not FDA-approved. No compounded product is. FDA approval applies to the branded drugs produced by the original manufacturer to their approved specifications.
- Compounded semaglutide is not a treatment or cure for diabetes or any other disease. GLP-1 receptor agonists have FDA-approved indications for specific branded products, but compounded formulations do not carry those approvals. Clinicians prescribe based on individual patient evaluation.
What should you do if your access situation changes?
If you are currently receiving compounded semaglutide and the regulatory landscape shifts, the most important thing is not to make abrupt changes without clinician guidance. GLP-1 receptor agonists affect appetite regulation, glucose metabolism, and gastrointestinal function. Stopping or changing doses without medical oversight can have unintended effects.
A licensed clinician can assess your situation and discuss the options that are clinically appropriate for you at the time of your consultation. Those options may include transitioning to a branded product, adjusting your weight management approach, or other pathways — depending on your goals and medical history.
Frequently asked questions
Is there a compound semaglutide ban?
The ban headlines track FDA policy toward compounded GLP-1s, which moved repeatedly during and after the semaglutide supply crunch of the early 2020s. The mechanism behind a compounded preparation is narrower than any headline: it is dispensed only against a prescription a licensed clinician writes for one named patient, prepared by a licensed 503A pharmacy in the USA, and it is not FDA-approved. A clinician can tell you what applies to your own prescription.
Can I still get compounded semaglutide?
That gets answered one patient at a time, by a clinician. A licensed prescriber reviews your health history and decides whether semaglutide is appropriate for you, and a licensed 503A pharmacy in the USA prepares what they write. PepScribe's semaglutide is a combination preparation with cyanocobalamin, dosed for the individual. Headlines cannot tell you what fits your own case.
Is compounded semaglutide the same as Ozempic or Wegovy?
Compounded semaglutide contains the same active ingredient as branded Ozempic and Wegovy, but it is not an FDA-approved drug and is not manufactured by Novo Nordisk. It is prepared by licensed 503A compounding pharmacies in the USA from bulk drug substances under a clinician's prescription. It is not the same as any branded product — never "the same as Ozempic."
What caused the semaglutide shortage in the first place?
Demand for semaglutide, driven by widespread adoption for weight management, outpaced Novo Nordisk's production capacity, and the FDA listed the branded injections in shortage. That period is when compounded semaglutide entered the public conversation and when most of the writing you can still find online was produced.
What should a patient do if their access to compounded semaglutide changes?
Do not stop semaglutide abruptly without medical guidance. If your access changes for any reason, a licensed clinician can work through the options with you, which may include a branded product, a different treatment plan, or another clinician-supervised approach. The right answer depends on your clinical history and goals.
Does PepScribe use overseas compounding pharmacies for semaglutide?
No. PepScribe works exclusively with licensed 503A compounding pharmacies in the USA. No hidden overseas supply chain. The sourcing standard is 503A-only — not 503B, not international, not gray-market.
